Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 4.85 is 35% below its 5-year average of 7.42, near the low end of its 5-year range (4.40–9.18).
As of the fiscal period ended Tuesday, June 30, 2026. 25.18% below its 12-month average of 6.48.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.85.
CURRENT RATIO
4.85
CURRENT RATIO AVG TTM
6.48
CURRENT RATIO AVG 3Y
8.01
CURRENT RATIO AVG 5Y
7.42
CURRENT RATIO AVG 10Y
7.30
CURRENT RATIO AVG 15Y
7.11
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-25.18%
CURRENT VS 3Y AVG
-39.52%
CURRENT VS 5Y AVG
-34.72%
CURRENT VS 10Y AVG
-33.64%
CURRENT VS 15Y AVG
-31.80%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.67
median of 830 covered companies
CURRENT VS SECTOR MEDIAN
+31.87%
vs the sector median at left
Fate Therapeutics, Inc.
Market Cap
$268.67M
Current Ratio
4.85
TTM Avg
6.48
3Y Avg
8.01
5Y Avg
7.42
Market Cap
$269.16M
Current Ratio
9.24
TTM Avg
7.84
3Y Avg
8.19
5Y Avg
10.90
Market Cap
$269.75M
Current Ratio
9.22
TTM Avg
6.22
3Y Avg
4.84
5Y Avg
4.06
Market Cap
$266.93M
Current Ratio
5.35
TTM Avg
2.41
3Y Avg
1.69
5Y Avg
2.06
Market Cap
$270.52M
Current Ratio
2.90
TTM Avg
4.46
3Y Avg
4.43
5Y Avg
4.81
Market Cap
$264.16M
Current Ratio
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
Market Cap
$264.03M
Current Ratio
8.88
TTM Avg
8.27
3Y Avg
7.75
5Y Avg
6.94
Market Cap
$262.09M
Current Ratio
15.82
TTM Avg
24.04
3Y Avg
14.70
5Y Avg
12.06
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fate Therapeutics, Inc. (FATE) | $268.67M | 4.85 | 6.48 | 8.01 | 7.42 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $269.16M | 9.24 | 7.84 | 8.19 | 10.90 |
| Scribe Therapeutics Inc. (SCTX)vs › | $267.73M | N/A | N/A | N/A | N/A |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.75M | 9.22 | 6.22 | 4.84 | 4.06 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.93M | 5.35 | 2.41 | 1.69 | 2.06 |
| Treace Medical Concepts, Inc. (TMCI)vs › | $270.52M | 2.90 | 4.46 | 4.43 | 4.81 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | 16.00 | 13.11 | 8.33 | 7.81 |
| OraSure Technologies, Inc. (OSUR)vs › | $264.03M | 8.88 | 8.27 | 7.75 | 6.94 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.09M | 15.82 | 24.04 | 14.70 | 12.06 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | 4.50 | 8.35 | 6.79 | 6.91 |
Current Ratio
4.85
Quick Ratio
4.85
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 4.85 |
| 2026-03-31 | 5.85 |
| 2025-12-31 | 5.79 |
| 2025-09-30 | 7.87 |
| 2025-06-30 | 8.04 |
| 2025-03-31 | 8.81 |
| 2024-12-31 | 7.58 |
| 2024-09-30 | 8.29 |
| 2024-06-30 | 9.18 |
| 2024-03-31 | 8.69 |
| 2023-12-31 | 8.48 |
| 2023-09-30 | 8.81 |
| 2023-06-30 | 8.78 |
| 2023-03-31 | 9.00 |
| 2022-12-31 | 4.40 |
| 2022-09-30 | 5.15 |
| 2022-06-30 | 6.55 |
| 2022-03-31 | 7.69 |
| 2021-12-31 | 7.79 |
| 2021-09-30 | 7.55 |
| 2021-06-30 | 6.75 |
| 2021-03-31 | 8.50 |
| 2020-12-31 | 5.78 |
| 2020-09-30 | 9.17 |
| 2020-06-30 | 11.92 |
| 2020-03-31 | 8.36 |
| 2019-12-31 | 8.17 |
| 2019-09-30 | 7.53 |
| 2019-06-30 | 5.61 |
| 2019-03-31 | 6.40 |
| 2018-12-31 | 7.53 |
| 2018-09-30 | 9.44 |
| 2018-06-30 | 4.92 |
| 2018-03-31 | 7.20 |
| 2017-12-31 | 9.29 |
| 2017-09-30 | 7.21 |
| 2017-06-30 | 8.92 |
| 2017-03-31 | 4.94 |
| 2016-12-31 | 6.14 |
| 2016-09-30 | 3.23 |
| 2016-06-30 | 3.29 |
| 2016-03-31 | 4.07 |
| 2015-12-31 | 4.88 |
| 2015-09-30 | 5.89 |
| 2015-06-30 | 7.21 |
| 2015-03-31 | 6.67 |
| 2014-12-31 | 10.89 |
| 2014-09-30 | 11.66 |
| 2014-06-30 | 11.08 |
| 2014-03-31 | 11.08 |
| 2013-12-31 | 11.88 |
| 2013-09-30 | 2.04 |
| 2013-06-30 | 0.75 |
| 2013-03-31 | 1.29 |
| 2012-12-31 | 2.02 |
| 2012-09-30 | 0.00 |
